Italian Agency Hits Chinese Heparin Manufacturer for GMP Violations

By Sam | February 5, 2019

The Italian Medicines Agency found serious GMP violations during an Oct. 31 inspection of a heparin manufacturing facility in China and recommended that the firm be prohibited from supplying crude heparin sodium to the EU.
Source: Drug GMP Report

Posted in Drug GMP Report